Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
Sales | 1,339 | 1,726 | 1,532 | 2,145 | 4,658 |
Gross Profit | 1,339 | 1,726 | 1,532 | 2,145 | 4,658 |
Operating Expenses | 22,779 | 23,309 | 20,895 | 22,892 | 26,216 |
Operating Income | -21,440 | -21,583 | -19,363 | -20,747 | -21,558 |
Interest Expense | 29 | 34 | 44 | 44 | 46 |
Other Income | 1,752 | 1,821 | 1,532 | 1,479 | 1,500 |
Pre-tax Income | -19,717 | -19,796 | -17,875 | -19,312 | -20,104 |
Net Income Continuous | -19,717 | -19,796 | -17,875 | -19,312 | -20,104 |
Net Income | $-19,717 | $-19,796 | $-17,875 | $-19,312 | $-20,104 |
EPS Basic Total Ops | -0.10 | -0.11 | -0.10 | -0.12 | -0.12 |
EPS Basic Continuous Ops | -0.10 | -0.11 | -0.10 | -0.11 | -0.12 |
EPS Diluted Total Ops | -0.10 | -0.11 | -0.10 | -0.12 | -0.12 |
EPS Diluted Continuous Ops | -0.10 | -0.11 | -0.10 | -0.11 | -0.12 |
EPS Diluted Before Non-Recurring Items | -0.10 | -0.11 | -0.10 | -0.12 | -0.12 |
EBITDA(a) | $-21,104 | $-21,227 | $-19,008 | $-20,388 | $-21,189 |